丝裂原活化蛋白激酶抑制剂联合酪氨酸激酶抑制剂帕瑞替尼可对抗细胞黏附介导的残留病并防止FLT3-ITD急性髓系白血病再扩增
该临床前研究利用原代人白血病-人基质细胞模型模拟患者体内的细胞间相互作用,检测了多种临床在用酪氨酸激酶抑制剂(TKI)消除基质驱动的白血病信号的能力,并鉴定出一种与丝裂原活化蛋白激酶(MEK)抑制剂的协同组合,可能用于微小残留病(MRD)场景。研究发现了一种常见的基质介导耐药机制,可能不依赖于突变状态,但可通过合理药物设计靶向,以清除MRD并减少治疗相关毒性。
要点
- 原代人白血病-人基质细胞模型用于模拟患者体内细胞间相互作用。
- 多种临床在用TKI消除基质驱动白血病信号的能力被检测。
- 鉴定出TKI与MEK抑制剂的协同组合,可能用于MRD场景。
核心结论
- 研究发现了一种常见的基质介导耐药机制,可能不依赖于突变状态,但可通过合理药物设计靶向,以清除MRD并减少治疗相关毒性。
研究设计与样本
- 临床前研究,使用原代人白血病-人基质细胞模型模拟患者体内的细胞间相互作用。
主要发现
- 检测了多种临床在用TKI消除基质驱动的白血病信号的能力,并鉴定出一种与MEK抑制剂的协同组合,可能用于MRD场景。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Minimal residual disease (MRD) in acute myeloid leukaemia (AML) poses a major challenge due to drug insensitivity and high risk of relapse. Intensification of chemotherapy and stem cell transplantation are often pivoted on MRD status. Relapse rates are high even with the integration of first-generation FMS-like tyrosine kinase 3 (FLT3) inhibitors in pre- and post-transplant regimes and as maintenance in FLT3-mutated AML. Pre-clinical progress is hampered by the lack of suitable modelling of residual disease and post-therapy relapse. In the present study, we investigated the nature of pro-survival signalling in primary residual tyrosine kinase inhibitor (TKI)-treated AML cells adherent to stroma and further determined their drug sensitivity in order to inform rational future therapy combinations. Using a primary human leukaemia-human stroma model to mimic the cell-cell interactions occurring in patients, the ability of several TKIs in clinical use, to abrogate stroma-driven leukaemic signalling was determined, and a synergistic combination with a mitogen-activated protein kinase (MEK) inhibitor identified for potential therapeutic application in the MRD setting. The findings reveal a common mechanism of stroma-mediated resistance that may be independent of mutational status but can be targeted through rational drug design, to eradicate MRD and reduce treatment-related toxicity.
引用
- Zabkiewicz J, Lazenby M, Edwards G, et al. Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia. Br J Haematol. 2020. PMID: 32394450. doi:10.1111/bjh.16665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。